Core Viewpoint - The stock of Giant Bio (02367) has declined nearly 4%, currently trading at HKD 36.82, with a transaction volume of HKD 241 million, following a report from CMB International that downgraded revenue growth forecasts for 2025/26 due to short-term pressures on Comfy [1] Group 1: Sales Performance - During the "Double Eleven" shopping festival, the company's sales were under pressure, primarily due to disappointing performance from the Comfy brand, which saw sales drop by 20% on Tmall and 50% on Douyin [1] - In contrast, the Collgene brand achieved positive growth during the same period, indicating a divergence in brand performance [1] Group 2: Strategic Adjustments - The company is actively adjusting its channel strategy in response to competitive pressures within the industry, while maintaining strategic focus to protect pricing and consumer experience [1] - Management has increased the proportion of self-broadcast channels, laying a foundation for long-term growth despite current challenges [1] Group 3: Financial Guidance - Management has lowered the earnings guidance for the current year, expecting revenue to be flat or slightly down year-on-year, and has revised profit forecasts to reflect a mid to high single-digit decline [1]
巨子生物跌近4% 可复美销售表现承压 管理层下调今年业绩指引